BCSCDB: Biomarkers of Cancer Stem Cells Database
Number of entries related to HT-1376 cell line is 77
| GENE | HGNC_ID | MARKER_TYPE | CANCER_TYPE | HISTOLOGICAL_TYPE | CELL_LINE | CSC_ENRICHMENT | METHOD | EXPRESSION_LEVEL | CONFIDENCE_SCORING | GLOBAL_SCORING | PUBMED_ID |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CD44 | 1681 | LTM | Bladder Cancer | Carcinoma | HT-1376 | NA | SFA followed by IF staining and qRT-PCR | NA | 0.44 | 1 | 26452033 |
| CD44 | 1681 | LTM | Bladder Cancer | Carcinoma | HT-1376 | NA | SFA and IF staining | NA | 0.44 | 1 | 33920080 |
| CD44 | 1681 | LTM | Bladder Cancer | Carcinoma | HT-1376 | NA | FACs | NA | 0.44 | 1 | 29340052 |
| BMI1 | 1066 | LTM | Bladder Cancer | Carcinoma | HT-1376 | NA | SFA and IF staining | NA | 0.24 | 0.1135 | 33920080 |
| ABCB1 | 40 | LTM | Bladder Cancer | Carcinoma | HT-1376 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0604 | 26452033 |
| ABCG2 | 74 | LTM | Bladder Cancer | Carcinoma | HT-1376 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.1739 | 26452033 |
| ALDH1A1 | 402 | LTM | Bladder Cancer | Carcinoma | HT-1376 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.684 | 26452033 |
| ALDH1A2 | 15472 | LTM | Bladder Cancer | Carcinoma | HT-1376 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.0117 | 26452033 |
| NANOG | 20857 | LTM | Bladder Cancer | Carcinoma | HT-1376 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.5461 | 26452033 |
| POU5F1 | 9221 | LTM | Bladder Cancer | Carcinoma | HT-1376 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.6448 | 26452033 |
| SOX2 | 11195 | LTM | Bladder Cancer | Carcinoma | HT-1376 | NA | SFA followed by qRT-PCR | NA | 0.2 | 0.5695 | 26452033 |
| ADAM7 | 214 | HTM | Bladder Cancer | Carcinoma | HT-1376 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29340052 |
| ADGRF1 | 18990 | HTM | Bladder Cancer | Carcinoma | HT-1376 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 29340052 |
| AMOT | 17810 | HTM | Bladder Cancer | Carcinoma | HT-1376 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 29340052 |
| APOB | 603 | HTM | Bladder Cancer | Carcinoma | HT-1376 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29340052 |
| ATP10B | 13543 | HTM | Bladder Cancer | Carcinoma | HT-1376 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| B4GALNT2 | 24136 | HTM | Bladder Cancer | Carcinoma | HT-1376 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| C16orf78 | 28479 | HTM | Bladder Cancer | Carcinoma | HT-1376 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29340052 |
| C2CD6 | 14438 | HTM | Bladder Cancer | Carcinoma | HT-1376 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| C5AR1 | 1338 | HTM | Bladder Cancer | Carcinoma | HT-1376 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29340052 |
| CARM1 | 23393 | HTM | Bladder Cancer | Carcinoma | HT-1376 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| CDKL4 | 19287 | HTM | Bladder Cancer | Carcinoma | HT-1376 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| CHST3 | 1971 | HTM | Bladder Cancer | Carcinoma | HT-1376 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 29340052 |
| CNN2 | 2156 | HTM | Bladder Cancer | Carcinoma | HT-1376 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 29340052 |
| CPA4 | 15740 | HTM | Bladder Cancer | Carcinoma | HT-1376 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0042 | 29340052 |
| DCSTAMP | 18549 | HTM | Bladder Cancer | Carcinoma | HT-1376 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 29340052 |
| DGCR8 | 2847 | HTM | Bladder Cancer | Carcinoma | HT-1376 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29340052 |
| DHRS9 | 16888 | HTM | Bladder Cancer | Carcinoma | HT-1376 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0064 | 29340052 |
| DMGDH | 24475 | HTM | Bladder Cancer | Carcinoma | HT-1376 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| DNAH12 | 2943 | HTM | Bladder Cancer | Carcinoma | HT-1376 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29340052 |
| DNAH9 | 2953 | HTM | Bladder Cancer | Carcinoma | HT-1376 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29340052 |
| ERBIN | 15842 | HTM | Bladder Cancer | Carcinoma | HT-1376 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| EYS | 21555 | HTM | Bladder Cancer | Carcinoma | HT-1376 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29340052 |
| FMN2 | 14074 | HTM | Bladder Cancer | Carcinoma | HT-1376 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29340052 |
| GLIPR1L1 | 28392 | HTM | Bladder Cancer | Carcinoma | HT-1376 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29340052 |
| GPSM1 | 17858 | HTM | Bladder Cancer | Carcinoma | HT-1376 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| GRIA4 | 4574 | HTM | Bladder Cancer | Carcinoma | HT-1376 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29340052 |
| GTF2E1 | 4650 | HTM | Bladder Cancer | Carcinoma | HT-1376 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 29340052 |
| HTR1B | 5287 | HTM | Bladder Cancer | Carcinoma | HT-1376 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29340052 |
| INSRR | 6093 | HTM | Bladder Cancer | Carcinoma | HT-1376 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29340052 |
| IPO11 | 20628 | HTM | Bladder Cancer | Carcinoma | HT-1376 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29340052 |
| JAKMIP2 | 29067 | HTM | Bladder Cancer | Carcinoma | HT-1376 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| KCNE1 | 6240 | HTM | Bladder Cancer | Carcinoma | HT-1376 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| KLF11 | 11811 | HTM | Bladder Cancer | Carcinoma | HT-1376 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| LCA5L | 1255 | HTM | Bladder Cancer | Carcinoma | HT-1376 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| LRRC71 | 26556 | HTM | Bladder Cancer | Carcinoma | HT-1376 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| LTB | 6711 | HTM | Bladder Cancer | Carcinoma | HT-1376 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29340052 |
| MCHR2 | 20867 | HTM | Bladder Cancer | Carcinoma | HT-1376 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29340052 |
| MFAP2 | 7033 | HTM | Bladder Cancer | Carcinoma | HT-1376 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| NKG7 | 7830 | HTM | Bladder Cancer | Carcinoma | HT-1376 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29340052 |
| NPAS3 | 19311 | HTM | Bladder Cancer | Carcinoma | HT-1376 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29340052 |
| OR10G9 | 15129 | HTM | Bladder Cancer | Carcinoma | HT-1376 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| OR1K1 | 8212 | HTM | Bladder Cancer | Carcinoma | HT-1376 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| OR2T27 | 31252 | HTM | Bladder Cancer | Carcinoma | HT-1376 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29340052 |
| OR6A2 | 15301 | HTM | Bladder Cancer | Carcinoma | HT-1376 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29340052 |
| PLA2G4C | 9037 | HTM | Bladder Cancer | Carcinoma | HT-1376 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0032 | 29340052 |
| PNLDC1 | 21185 | HTM | Bladder Cancer | Carcinoma | HT-1376 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29340052 |
| POTEC | 33894 | HTM | Bladder Cancer | Carcinoma | HT-1376 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| PTPN20 | 23423 | HTM | Bladder Cancer | Carcinoma | HT-1376 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29340052 |
| PXT1 | 18312 | HTM | Bladder Cancer | Carcinoma | HT-1376 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| ROBO2 | 10250 | HTM | Bladder Cancer | Carcinoma | HT-1376 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 29340052 |
| RTP1 | 28580 | HTM | Bladder Cancer | Carcinoma | HT-1376 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29340052 |
| SAA2 | 10514 | HTM | Bladder Cancer | Carcinoma | HT-1376 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29340052 |
| SLC4A9 | 11035 | HTM | Bladder Cancer | Carcinoma | HT-1376 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0011 | 29340052 |
| SLCO1A2 | 10956 | HTM | Bladder Cancer | Carcinoma | HT-1376 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29340052 |
| SLIT1 | 11085 | HTM | Bladder Cancer | Carcinoma | HT-1376 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0021 | 29340052 |
| STOM | 3383 | HTM | Bladder Cancer | Carcinoma | HT-1376 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0032 | 29340052 |
| TAS2R8 | 14915 | HTM | Bladder Cancer | Carcinoma | HT-1376 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29340052 |
| TCTE3 | 11695 | HTM | Bladder Cancer | Carcinoma | HT-1376 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29340052 |
| TMEM114 | 33227 | HTM | Bladder Cancer | Carcinoma | HT-1376 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29340052 |
| TNFAIP2 | 11895 | HTM | Bladder Cancer | Carcinoma | HT-1376 | NA | FACs for CSC marker followed by Transcriptomics | Down | 0.04 | 0.0021 | 29340052 |
| TNFRSF9 | 11924 | HTM | Bladder Cancer | Carcinoma | HT-1376 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29340052 |
| TPD52L3 | 23382 | HTM | Bladder Cancer | Carcinoma | HT-1376 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29340052 |
| TRPC4 | 12336 | HTM | Bladder Cancer | Carcinoma | HT-1376 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29340052 |
| URB1 | 17344 | HTM | Bladder Cancer | Carcinoma | HT-1376 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29340052 |
| USP2 | 12618 | HTM | Bladder Cancer | Carcinoma | HT-1376 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29340052 |
| ZHX1 | 12871 | HTM | Bladder Cancer | Carcinoma | HT-1376 | NA | FACs for CSC marker followed by Transcriptomics | Up | 0.04 | 0.0011 | 29340052 |